A Phase 2 interventional study of Anakinra in Myeloproliferative Neoplasm, sponsored by University Hospital, Brest. Not yet recruiting at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University Hospital, Brest · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Myeloproliferative Disorders by University Hospital, Brest — 3 open to participants now, 6 under way, none of them phase 3. Myeloproliferative Disorders · University Hospital, Brest.
Among the 10 studies in Myeloproliferative Disorders by University Hospital, Brest, this one is the only one that started in 2027, is the only one in phase 2, and was the 10th registered.
667 studies on the registry are indexed under Myeloproliferative Disorders; 110 are open to participants now.
Browse Myeloproliferative Disorders studies →3 of the 10 studies in Myeloproliferative Disorders by University Hospital, Brest are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Brest · Sites in France
Ages 18+
University Hospital, Brest · Sites in France
Ages 0–30
By country, each count listing its studies:
Of the 87 Myeloproliferative Disorders studies recruiting now, 63 (72%) set no upper age limit and 18 (21%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 47 across 462 interventional studies indexed under Myeloproliferative Disorders.
Median enrollment 57 across the 2 interventional studies, 135 across the 8 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Brest is the lead sponsor of 602 studies on the registry; 137 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Myeloproliferative Disorders by University Hospital, Brest, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Myeloproliferative neoplasms (MPNs) - polycythemia vera, essential thrombocythemia, and primary myelofibrosis - are characterized by excessive myeloid proliferation driven by mutations affecting the JAK2, CALR, and MPL genes, resulting in constitutive activation of hematopoietic cytokine signaling pathways. These hematological malignancies carry an increased risk of thrombosis and may evolve toward secondary myelofibrosis or acute leukemia. Bone marrow inflammation, particularly through interleukin-1 (IL-1), plays a major role in clonal expansion and the clinical expression of these diseases, as demonstrated by preclinical models showing the beneficial effect of its inhibition.
Anakinra, an IL-1 receptor antagonist widely used in rheumatology but never evaluated in MPNs, represents a promising therapeutic option. This proof-of-concept study will randomize 50 patients with a suboptimal response to cytoreductive therapy into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or cytoreductive therapy alone (n=25). The primary endpoint will be the reduction in serum calprotectin levels, a key inflammatory marker of the IL-1 loop that has recently demonstrated prognostic relevance in MPNs. Secondary endpoints will include improvements in hematological parameters, driver mutation allelic burden, pro-inflammatory cytokines, and quality of life.
This study represents an essential step toward larger trials aimed at demonstrating a durable reduction in thrombotic risk and disease progression.
Eligible patients will be identified during routine follow-up visits. After signature of informed consent and confirmation of all eligibility criteria - including a negative urine pregnancy test for women of childbearing potential - patients will be randomized into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or ongoing cytoreductive therapy alone (n=25), for a duration of 3 months.
Clinical and laboratory assessments (CBC, CRP, circulating CD34+ cells, allelic burden, calprotectin, cytokines, quality of life) will be performed at baseline, at 3 months, and at 6 months. An additional visit at 1 month is planned in the anakinra arm to assess tolerability. Patients may withdraw at any time, with reasons documented in the eCRF.
The addition of an anti-IL-1 treatment to cytoreductive therapy could improve its efficacy by promoting control of the mutated clone, which is poorly targeted by current cytoreductive agents other than interferon-α, often poorly tolerated. Better clonal control could limit phenotypic progression, reduce thrombotic risk, and improve hematological response, particularly in the megakaryocytic lineage.
The impact on myelofibrosis, observed in mice, and the improvement in quality of life through reduction of systemic inflammation remain to be confirmed in humans. Not all patients will necessarily benefit from this approach, justifying this exploratory study to evaluate its potential and feasibility.
The risks associated with anakinra are predictable and well documented (local reactions, minor systemic effects, infectious risk), mitigated by the short treatment duration and close monitoring. The benefit-risk ratio is considered favorable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anakinra 100 mg/day subcutaneously for 3 months, added to ongoing standard cytoreductive therapy (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. Additional Month 1 safety/tolerability visit (clinical exam, routine biology, AE/SAE and injection-site reaction review, compliance check) and an injection diary for adherence.
Drug: Anakinra
Standard cytoreductive therapy continued alone, with no additional study treatment (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. No Month 1 visit.
Recombinant human interleukin-1 receptor antagonist (Kineret 100 mg/0.67 mL prefilled syringe). Administered at 100 mg once daily by subcutaneous injection for 3 months, in addition to ongoing standard cytoreductive therapy. Self-injection or home-nurse administration; adherence tracked via injection diary.
Change in serum calprotectin levels
Calprotectin levels are measured on serum samples by centralized analysis (µg/mL)
Time frame: Baseline and Month 3
Improvement (yes/no) of the response status between baseline and month 3.
Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).
Time frame: Month 3
Improvement (yes/no) of the response status between baseline and month 6.
Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).
Time frame: Month 6
Improvement (yes/no) of the response status between month 3 and month 6.
Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).
Time frame: Month 6
Hemoglobin count
Measurement of Hemoglobin in g/dL
Time frame: Baseline
Hematocrit count
Measurement of Hematocrit in %
Time frame: Baseline
White blood cell count
Measurement of WBC in G/L
Time frame: Baseline
Platelet cell count
Measurement of Platelets in G/L
Time frame: Baseline
Hemoglobin count
Measurement of Hemoglobin in g/dL
Time frame: Month 3
Hematocrit count
Measurement of Hematocrit in %
Time frame: Month 3
White blood cell count
Measurement of WBC in G/L
Time frame: Month 3
Platelet cell count
Measurement of Platelets in G/L
Time frame: Month 3
Hemoglobin count
Measurement of Hemoglobin in g/dL
Time frame: Month 6
Hematocrit count
Measurement of Hematocrit in %
Time frame: Month 6
White blood cell count
Measurement of WBC in G/L
Time frame: Month 6
Platelet cell count
Measurement of Platelets in G/L
Time frame: Month 6
Treatment-related adverse event for experimental group
A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).
Time frame: Month 1
Treatment-related adverse event for experimental group
A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).
Time frame: Month 3
Treatment-related adverse event for experimental group
A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).
Time frame: Month 6
Adherence to treatment regimen for experimental group
Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between baseline and month 1. Days with missing diary entries will be excluded from the calculation.
Time frame: Month 1
Adherence to treatment regimen for experimental group
Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 1 and month 2. Days with missing diary entries will be excluded from the calculation
Time frame: Month 2
Adherence to treatment regimen for experimental group
Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 2 and month 3. Days with missing diary entries will be excluded from the calculation.
Time frame: Month 3
QLQ-C30 Summary Score
The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.
Time frame: Baseline
QLQ-C30 Summary Score
The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.
Time frame: Month 3
QLQ-C30 Summary Score
The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.
Time frame: Month 6
Global health status / QoL score
Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.
Time frame: Baseline
Global health status / QoL score
Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.
Time frame: Month 3
Global health status / QoL score
Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.
Time frame: Month 6
Patient-reported symptom severity over the previous 4 weeks for pruritus
Defined as the score on a 10-point Visual Analog Scale
Time frame: Baseline
Patient-reported symptom severity over the previous 4 weeks for fever
Defined as the score on a 10-point Visual Analog Scale
Time frame: Baseline
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Defined as the score on a 10-point Visual Analog Scale
Time frame: Baseline
Patient-reported symptom severity over the previous 4 weeks for pruritus
Defined as the score on a 10-point Visual Analog Scale
Time frame: Month 3
Patient-reported symptom severity over the previous 4 weeks for fever
Defined as the score on a 10-point Visual Analog Scale
Time frame: Month 3
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Defined as the score on a 10-point Visual Analog Scale
Time frame: Month 3
Patient-reported symptom severity over the previous 4 weeks for pruritus
Defined as the score on a 10-point Visual Analog Scale
Time frame: Month 6
Patient-reported symptom severity over the previous 4 weeks for fever
Defined as the score on a 10-point Visual Analog Scale
Time frame: Month 6
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Defined as the score on a 10-point Visual Analog Scale
Time frame: Month 6
Inflammatory biological profile
Measurement of IL-1β cytokines in pg/mL.
Time frame: Baseline
Inflammatory biological profile
Measurement of IL-1β cytokines in pg/mL.
Time frame: Month 3
Inflammatory biological profile
Measurement of IL-1β cytokines in pg/mL.
Time frame: Month 6
Inflammatory biological profile
Measurement of IL-6 cytokines in pg/mL.
Time frame: Baseline
Inflammatory biological profile
Measurement of IL-6 cytokines in pg/mL.
Time frame: Month 3
Inflammatory biological profile
Measurement of IL-6 cytokines in pg/mL.
Time frame: Month 6
Inflammatory biological profile
Measurement of IL-8 cytokines in pg/mL.
Time frame: Baseline
Inflammatory biological profile
Measurement of IL-8 cytokines in pg/mL.
Time frame: Month 3
Inflammatory biological profile
Measurement of IL-8 cytokines in pg/mL.
Time frame: Month 6
Inflammatory biological profile
Measurement of MIP-1β cytokines in pg/mL.
Time frame: Baseline
Inflammatory biological profile
Measurement of MIP-1β cytokines in pg/mL.
Time frame: Month 3
Inflammatory biological profile
Measurement of MIP-1β cytokines in pg/mL.
Time frame: Month 6
Inflammatory biological profile
Measurement of TNF-α cytokines in pg/mL.
Time frame: Baseline
Inflammatory biological profile
Measurement of TNF-α cytokines in pg/mL.
Time frame: Month 3
Inflammatory biological profile
Measurement of TNF-α cytokines in pg/mL.
Time frame: Month 6
Allele burden of the driver mutation
Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.
Time frame: Baseline
Allele burden of the driver mutation
Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.
Time frame: Month 3
Allele burden of the driver mutation
Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.
Time frame: Month 6
Allele burden of the driver mutation
Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.
Time frame: Baseline
Allele burden of the driver mutation
Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.
Time frame: Month 3
Allele burden of the driver mutation
Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.
Time frame: Month 6
Allele burden of the driver mutation
Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.
Time frame: Baseline
Allele burden of the driver mutation
Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.
Time frame: Month 3
Allele burden of the driver mutation
Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.
Time frame: Month 6
Fibrosis markers
Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.
Time frame: Baseline
Fibrosis markers
Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.
Time frame: Month 3
Fibrosis markers
Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.
Time frame: Month 6
Start is estimated for Feb 2027; primary completion for Aug 2028, 18 months later.
Of 74 non-industry phase 2 interventional studies under Myeloproliferative Disorders, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 118. This study's planned 18 months is below that.
Counting every sponsor, half of 87 studies reached it within 68 months; a quarter within 37 and three quarters within 111.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Myeloproliferative Disorders →